X
Search Filters
Format Format
Subjects Subjects
Subjects Subjects
X
Sort by Item Count (A-Z)
Filter by Count
index medicus (124) 124
humans (108) 108
male (88) 88
female (71) 71
glycopyrrolate (56) 56
adult (44) 44
middle aged (44) 44
glycopyrrolate - therapeutic use (40) 40
glycopyrrolate - analogs & derivatives (38) 38
glycopyrrolate - administration & dosage (37) 37
glycopyrrolate - pharmacology (33) 33
pulmonary disease, chronic obstructive - drug therapy (33) 33
respiratory system (32) 32
double-blind method (31) 31
aged (30) 30
treatment outcome (29) 29
animals (26) 26
heart rate - drug effects (23) 23
tiotropium (23) 23
glycopyrrolate - adverse effects (22) 22
obstructive pulmonary-disease (22) 22
bronchodilator agents - administration & dosage (21) 21
pharmacology & pharmacy (21) 21
double-blind (20) 20
bronchodilator agents - therapeutic use (19) 19
indans - administration & dosage (19) 19
quinolones - administration & dosage (19) 19
abridged index medicus (18) 18
indans - therapeutic use (18) 18
lung diseases, obstructive (18) 18
quinolones - therapeutic use (18) 18
atropine (17) 17
copd (17) 17
drug therapy (17) 17
drug combinations (16) 16
drug therapy, combination (16) 16
efficacy (16) 16
indacaterol (16) 16
time factors (15) 15
anesthesiology (14) 14
muscarinic antagonists - therapeutic use (14) 14
safety (14) 14
bronchodilator agents - adverse effects (13) 13
dosage and administration (13) 13
indans - adverse effects (13) 13
pulmonary disease, chronic obstructive - physiopathology (13) 13
quinolones - adverse effects (13) 13
tiotropium bromide (13) 13
administration, inhalation (12) 12
chronic obstructive pulmonary disease (12) 12
formoterol (12) 12
management (12) 12
muscarinic antagonists - administration & dosage (12) 12
pulmonary/respiratory (12) 12
research (12) 12
care and treatment (11) 11
muscarinic antagonists - adverse effects (11) 11
muscarinic antagonists - pharmacology (11) 11
adolescent (10) 10
blood pressure - drug effects (10) 10
drugs (10) 10
in vitro techniques (10) 10
anesthesia (9) 9
cholinergic antagonists - pharmacology (9) 9
dose-response relationship, drug (9) 9
forced expiratory volume - drug effects (9) 9
guinea pigs (9) 9
quality of life (9) 9
rats (9) 9
analysis (8) 8
cross-over studies (8) 8
parasympatholytics - pharmacology (8) 8
pharmacokinetics (8) 8
physiology (8) 8
prospective studies (8) 8
pulmonary disease, chronic obstructive - diagnosis (8) 8
salmeterol (8) 8
severity of illness index (8) 8
sialorrhea (8) 8
surgery (8) 8
adrenergic beta-2 receptor agonists - adverse effects (7) 7
albuterol - analogs & derivatives (7) 7
atropine - pharmacology (7) 7
cardiac & cardiovascular systems (7) 7
children (7) 7
drug administration schedule (7) 7
glycopyrronium (7) 7
medicine & public health (7) 7
mortality (7) 7
neostigmine (7) 7
pediatrics (7) 7
pulmonary and respiratory medicine (7) 7
pyrrolidines - pharmacology (7) 7
rabbits (7) 7
receptors, muscarinic - metabolism (7) 7
risk factors (7) 7
scopolamine derivatives - therapeutic use (7) 7
therapy (7) 7
anesthesia, general (6) 6
bronchodilator agents (6) 6
more...
Language Language
Publication Date Publication Date
Click on a bar to filter by decade
Slide to change publication date range


Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 1, pp. 51 - 60
Journal Article
European Respiratory Journal, ISSN 0903-1936, 12/2013, Volume 42, Issue 6, pp. 1484 - 1494
Journal Article
Lancet Respiratory Medicine, The, ISSN 2213-2600, 2013, Volume 1, Issue 3, pp. 199 - 209
Summary Background We evaluated the effect of dual, longacting inhaled bronchodilator treatment on exacerbations in patients with severe and very severe... 
Pulmonary/Respiratory | INDACATEROL | PROPIONATE | THERAPY | EFFICACY | RESPIRATORY SYSTEM | LUNG-FUNCTION | PREVENTION | OUTCOMES | HEALTH-STATUS | COPD | SALMETEROL | CRITICAL CARE MEDICINE | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Dose-Response Relationship, Drug | Quinolones - adverse effects | Scopolamine Derivatives - administration & dosage | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Respiratory Function Tests - methods | Administration, Inhalation | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Disease Progression | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Respiratory System - drug effects | Respiratory System - physiopathology | Aged | Drug Monitoring | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Index Medicus | Clinical Medicine | Lungmedicin och allergi | Medical and Health Sciences | Klinisk medicin | Medicin och hälsovetenskap | Respiratory Medicine and Allergy
Journal Article
Journal Article
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2014, Volume 108, Issue 4, pp. 584 - 592
Summary Introduction QVA149 is a novel, inhaled, once-daily dual bronchodilator containing a fixed-dose combination of the long-acting β2 -agonist indacaterol... 
Pulmonary/Respiratory | QVA149 | Tiotropium | Chronic obstructive pulmonary disease | Exercise | Hyperinflation | PLACEBO | CARDIAC & CARDIOVASCULAR SYSTEMS | DAILY NVA237 | EFFICACY | SAFETY | BRONCHODILATION | OBSTRUCTIVE PULMONARY-DISEASE | RESPIRATORY SYSTEM | TWICE-DAILY SALMETEROL | ONCE-DAILY INDACATEROL | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Exercise Tolerance - drug effects | Indans - therapeutic use | Lung Volume Measurements | Vital Capacity - drug effects | Quinolones - adverse effects | Spirometry - methods | Quinolones - therapeutic use | Adult | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Cross-Over Studies | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Aged | Pulmonary Disease, Chronic Obstructive - drug therapy | Medicine, Experimental | Medical research | Lung diseases, Obstructive | Confidence intervals | Drug therapy | Index Medicus
Journal Article
Journal Article
Thorax, ISSN 0040-6376, 06/2015, Volume 70, Issue 6, pp. 519 - 527
Journal Article
International Journal of COPD, ISSN 1176-9106, 06/2015, Volume 10, pp. 1015 - 1026
Background: The current Global initiative for chronic Obstructive Lung Disease (GOLD) treatment strategy recommends the use of one or more bronchodilators... 
Clinical trial | agonists | Long-acting muscarinic antagonist | Long-acting β | COPD | clinical trial | COST-EFFECTIVENESS | SAFETY | INHALED CORTICOSTEROIDS | SALMETEROL | FORMOTEROL | OBSTRUCTIVE PULMONARY-DISEASE | PRIMARY-CARE | FLUTICASONE PROPIONATE | RESPIRATORY SYSTEM | DOUBLE-BLIND | TIOTROPIUM | long-acting beta-agonists | long-acting muscarinic antagonist | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Spirometry | Glucocorticoids - administration & dosage | Glucocorticoids - therapeutic use | Bronchodilator Agents - administration & dosage | Humans | Middle Aged | Muscarinic Antagonists - adverse effects | Male | Fluticasone-Salmeterol Drug Combination - therapeutic use | Pulmonary Disease, Chronic Obstructive - physiopathology | Muscarinic Antagonists - therapeutic use | Indans - therapeutic use | Recovery of Function | Fluticasone-Salmeterol Drug Combination - adverse effects | Forced Expiratory Volume | Quinolones - adverse effects | Time Factors | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Adrenergic beta-2 Receptor Agonists - therapeutic use | Adult | Female | Surveys and Questionnaires | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Glucocorticoids - adverse effects | Glycopyrrolate - adverse effects | Severity of Illness Index | Pulmonary Disease, Chronic Obstructive - diagnosis | Double-Blind Method | Glycopyrrolate - therapeutic use | Administration, Inhalation | Treatment Outcome | Lung - physiopathology | Glycopyrrolate - analogs & derivatives | Fluticasone-Salmeterol Drug Combination - administration & dosage | Muscarinic Antagonists - administration & dosage | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Lung - drug effects | Adrenergic beta-2 Receptor Agonists - administration & dosage | Aged | Nebulizers and Vaporizers | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Drug therapy, Combination | Comparative analysis | Drug therapy | Methods | Bronchodilator agents | Index Medicus
Journal Article
Respiratory Medicine, ISSN 0954-6111, 2013, Volume 107, Issue 10, pp. 1558 - 1567
Journal Article
Thorax, ISSN 0040-6376, 04/2015, Volume 70, Issue 4, pp. 311 - 319
Background QVA149 is a once-daily (o.d.) inhaled dual bronchodilator containing a fixed-dose combination of the long-acting β2-agonist indacaterol and the... 
INDACATEROL | THERAPY | RESPIRATORY SYSTEM | DAILY SALMETEROL | DUAL BRONCHODILATION | LUNG-FUNCTION | DOUBLE-BLIND | EXACERBATIONS | OUTCOMES | GLYCOPYRRONIUM | HEALTH-STATUS | Bronchodilator Agents - therapeutic use | Indans - adverse effects | Ethanolamines - adverse effects | Formoterol Fumarate | Bronchodilator Agents - administration & dosage | Forced Expiratory Volume - drug effects | Humans | Middle Aged | Male | Pulmonary Disease, Chronic Obstructive - physiopathology | Ethanolamines - administration & dosage | Indans - therapeutic use | Vital Capacity - drug effects | Quinolones - adverse effects | Adrenergic beta-2 Receptor Agonists - adverse effects | Quinolones - therapeutic use | Scopolamine Derivatives - administration & dosage | Adrenergic beta-2 Receptor Agonists - therapeutic use | Female | Indans - administration & dosage | Bronchodilator Agents - adverse effects | Scopolamine Derivatives - therapeutic use | Scopolamine Derivatives - adverse effects | Tiotropium Bromide | Glycopyrrolate - adverse effects | Double-Blind Method | Drug Administration Schedule | Glycopyrrolate - therapeutic use | Treatment Outcome | Glycopyrrolate - analogs & derivatives | Quinolones - administration & dosage | Glycopyrrolate - administration & dosage | Quality of Life | Adrenergic beta-2 Receptor Agonists - administration & dosage | Ethanolamines - therapeutic use | Aged | Drug Combinations | Pulmonary Disease, Chronic Obstructive - drug therapy | Lung diseases, Obstructive | Care and treatment | Analysis | Formoterol | Indacaterol | Dosage and administration | Diagnosis | Quality of life | Index Medicus | 1506 | Chronic Obstructive Pulmonary Disease | COPD Pharmacology
Journal Article
Journal Article